



20th KM Hosur Road, Electronics City, Bangalore 560 100

For Immediate Release

Bangalore, 12 January 2012

Biocon's Q3 & 9M FY2012 Results Conference Call

At 3:00 pm IST on 25 January 2012

The management team of Biocon Limited will organize a **conference call for analysts and investors on Wednesday, 25 January 2012 at 3:00 pm IST** following the announcement of financial results for the quarter and nine months ended December 31, 2011.

The call will be initiated with a brief management discussion on the Q3 & 9M FY2012 performance followed by an interactive Question & Answer session. Ms. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited, and other members of the senior management team will represent Biocon on the conference call.

Details of the conference call are as under:

Date:	Wednesday, 25 January 2012
Time:	3:00 pm IST
Dial-in Numbers:	
Toll Free Number (India Only)	1800 102 1300 (India Toll Free numbers are accessible through all mobiles and landline services)
Direct Access Number (India Only)	1860 200 3399
Direct Access Number (International)	+91-44- 2370 2370
USA Toll Free	1800 974 0768 / 1866 380 1660
UK Toll Free	0808 101 6864 / 0808 101 7155
HK Toll Free	800 903 171 / 800 962 771
Replay Facility	Available on 25 January 2012 – 1 February 2012 on the same dial-in numbers mentioned above <i>The replay facility will begin after the call ends</i>

The transcript of the conference call will be available within 7 working days of the call on the corporate website: www.biocon.com

About Biocon

Biocon Limited (**BSE code:** 532523, **NSE Id:** BIOCON, **ISIN Id:** INE376G01013) is India's premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Established in 1978 by Dr. Kiran Mazumdar-Shaw, the group is an integrated, innovation-driven healthcare enterprise with offerings that traverse the entire drug development value chain. Balancing its novel molecule research pipeline with a diversified product portfolio, Biocon delivers affordable solutions to partners and customers in over 70 countries across the globe. Many of these products have USFDA and EMA acceptance. Stellar products from Biocon's stable include the world's first *Pichia* based recombinant human Insulin, INSUGEN[®] and glargine, BASALOG[®] coupled with a state of the art insulin pen device, INSUPen[®] and India's first indigenously produced monoclonal antibody BIOMAb-EGFR[®].

For more information, visit www.biocon.com

For further information please contact:

Jill Deviprasad
Biocon Limited
Tel: +91 80 2808 2054
Fax: +91 80 2852 3423
Email: jill.deviprasad@biocon.com

Urvashi Butani
Citigate Dewe Rogerson
Tel: +91 22 6645 1219
Fax: +91 22 6645 1213
Email: urvashi@cdr-india.com

Disclaimer: *Certain statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. There can be no assurance that future developments affecting Biocon and its subsidiaries / associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Biocon does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.*